IJERPH, Vol. 20, Pages 2565: Safety of Combined Targeted and Helixor & reg; & nbsp;Viscum album L. Therapy in Breast and Gynecological Cancer Patients, a Real-World Data Study
Conclusions: The present study is the first of its kind showing the applicability of Helixor® VA in combination with targeted therapies. The results indicate that add-on Helixor® VA does not negatively alter the safety profile of targeted therapies in breast and gynaecological cancer patients.
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Friedemann Schad Anja Thronicke Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Environmental Health | International Medicine & Public Health | Medical Ethics | Mistletoe | OBGYN | Study